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http://www.biomedcentral.com/1471-2474/14/356STUDY PROTOCOL Open AccessThe effect of high dose antibiotic impregnated
cement on rate of surgical site infection after hip
hemiarthroplasty for fractured neck of femur: a
protocol for a double-blind quasi randomised
controlled trial
Andrew P Sprowson1*, Cyrus D Jensen2, Sanjay Gupta2, Nick Parsons1, Aradhyula N Murty2, Simon MG Jones2,
Dominic Inman2 and Mike R Reed2Abstract
Background: Mortality following hip hemiarthroplasty is in the range of 10-40% in the first year, with much attributed
to post-operative complications. One such complication is surgical site infection (SSI), which at the start of this trial
affected 4.68% of patients in the UK having this operation. Compared to SSI rates of elective hip surgery, at less than
1%, this figure is elevated. The aim of this quasi randomised controlled trial (RCT) is to determine if high dose antibiotic
impregnated cement can reduce the SSI in patients at 12-months after hemiarthroplasty for intracapsular fractured neck
of femur.
Methods: 848 patients with an intracapsular fractured neck of femur requiring a hip hemiarthroplasty are been
recruited into this two-centre double-blind quasi RCT. Participants were recruited before surgery and quasi randomised
to standard care or intervention group. Participants, statistician and outcome assessors were blind to treatment allocation
throughout the study. The intervention consisted of high dose antibiotic impregnated cement consisting of 1 gram
Clindamycin and 1 gram of Gentamicin. The primary outcome is Health Protection Agency (HPA) defined deep surgical
site infection at 12 months. Secondary outcomes include HPA defined superficial surgical site infection at 30 days, 30
and 90-day mortality, length of hospital stay, critical care stay, and complications.
Discussion: Large randomised controlled trials assessing the effectiveness of a surgical intervention are uncommon,
particularly in the speciality of orthopaedics. The results from this trial will inform evidence-based recommendations for
antibiotic impregnated cement in the management of patients with a fractured neck of femur undergoing a hip
hemiarthroplasty. If high dose antibiotic impregnated cement is found to be an effective intervention, implementation
into clinical practice could improve long-term outcomes for patients undergoing hip hemiarthroplasty.
Trial registration: Current Controlled Trials: ISRCTN25633145* Correspondence: a.p.sprowson@warwick.ac.uk
1Warwick Medical School, The University of Warwick, Coventry CV4 7AL, UK
Full list of author information is available at the end of the article
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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With an increasingly elderly and growing population,
the number of osteoporotic fractures will steadily in-
crease over the next few decades [1]. In the UK over the
next 40 years, the number of people over 60 years will
rise by around 50%, and the number of those over
90 years of age will double [2]. A neck of femur fracture
(NOF) is one of the most common emergency surgical
procedures, often as a result of osteoporosis, with an
estimate of 120,000 occurring annually by 2015 in the
National Health Service (NHS) [3]. Direct medical costs
to the UK healthcare economy were £1.8 billion in 2000,
with the potential to increase to £2.2 billion by 2025,
with most of these costs relating directly to post-
operative care [4]. With this comes an increased clinical
workload of patients with NOF fractures, and subse-
quent complications secondary to surgery.
These patients can be broadly split into two distinct
groups, based on the fracture site and subsequent treat-
ment; (i) intertrochanteric fractures (extracapsular), treated
with dynamic hip screw or cannulated screws and (ii) in-
tracapsular NOF fractures, which if displaced are either
treated with a total hip replacement (THR), bipolar pros-
thesis (BP) or hemiarthroplasty. Based on the 2012
National Hip Fracture Database (NHFD) figures 23% of
undisplaced and 60.7% of displaced intracapsular fractured
NOF were treated with cemented hemiarthroplasties [5].
Dr Foster Intelligence published a Good Hospital
Guide in 2005/6, which found that there were 68,000
hip fracture patients treated that year, with mortality be-
ing 10% at 30 days, 20% at 4 months and 30% at 1 year
after admission. The global literature confirms rates in
the range 10-40% in the first year [6-8], with much of
this attributed to post-operative complications. One such
complication is SSI, which was documented on com-
mencement of this trial at 4.08% in patients undergoing
this procedure based on the 2007 HPA report [9]. Com-
pared to complication rates of elective hip surgery at
0.91%, the figure is over four times higher. It has been
suggested in the literature that the higher rate is due to
increased age and other underlying co morbidities. How-
ever a recent large study looked at 169,145 fracture cases
and 524,010 controls [10], and concluded that patients
with a hip fracture have a pronounced excess mortality
risk linked to the fracture event and postoperative
complication and not to pre-existing co-morbidity. In
addition, a patient’s post-operative stay in hospital for
this procedure is longer than those undergoing elective
hip or knee replacement and therefore the chance of
getting an infection is thought to increase [11]. This there-
fore indicates that as healthcare providers, we should aim
to target a decrease in postoperative complications.
One well established approach in orthopaedics is the use
of various antibiotics. Antibiotics, such as gentamicin arecommonly administered locally (in the cement) or paren-
terally. In a review of 15000 primary total hip replace-
ments from the Norwegian Arthroplasty Register the
lowest risk of revision was found in patients who received
both systemic and local (in cement) antibiotics [12]. Use
of parenteral and antibiotics in cement is standard practice
in the UK for cemented hemiarthroplasty [4]. This trial
aims to establish if a high dose antibiotic regime has fewer
infections compared to normal dose antibiotic cement.
Methods
The Fractured Hip Infection Trial (FHIT) is an on-going
two-centre double blind quasi-randomised controlled
trial conducted at Northumbria NHS Foundation Trust,
one of the largest elective orthopaedic centres in the
UK. The study has been approved by Newcastle and
North Tyneside Research Ethics Committee [2] (07/
H0901/63) and all participants provide informed, written
consent. Specific permission was gained for patients with
impaired mental capacity. The trial has been registered
with Current Controlled Trials (ISRCTN25633145).
Study duration
Recruitment into the trial began in November 2008, all
participants are now recruited and the 12-month follow-
up stage will be completed in 2013.
Participant recruitment
Potential participants were screened and recruited by
research associates or trained medical staff using Good
Clinical Practice (GCP) the following morning after
admission. Capacity to give consent was assessed on
admission to the orthopaedic ward and at the time con-
sent was taken. Those participants with normal mental
capacity underwent standard consent having their pref-
erences discussed and their agreement to treatment
sought. Non capable participants had consent gained by
their next of kin or, if they were unavailable, by a senior
member of nursing staff, not involved in the study. The
decision regarding capacity was made by a senior mem-
ber of medical staff and confirmed by the treating ortho-
paedic consultant. If the participant lacked capacity and
had not previously expressed their wishes, their frac-
tured neck of femur was treated in line with national
practice. Inclusion criteria include being listed for a hip
hemiarthroplasty for fractured neck of femur and being
willing to provide fully informed consent, or fulfil the
above-defined criteria. In this pragmatic trial setting,
inclusion criteria stated any patient with an intracapsular
fractured neck of femur deemed suitable for a hip hemi-
arthroplasty and the only exclusion criterion is that
patients must not be under 18 years of age. In order
to explore generalisability (the patients enrolled in the
study being representative of those undergoing hip
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der was recorded for all eligible patients.
Participant allocation
Frail patients sustain a fractured neck of femur at random
times and are transferred along geographical boundaries
to one of the two participating hospitals. Both units under-
take surgery with >95% of these patients undergoing sur-
gery within 48 hours (NHFD report 2012), with timely
surgery being incentivised by payments of £1335 per pa-
tient [5]. This approach ensured the surgeon had little
capacity to influence participant treatment allocation.
Treatment group allocation was based upon the date
surgery was performed. This allocation was based on a
monthly hospital assignment into one of the two groups,
each centre providing one treatment for the whole calen-
dar month. The following month this process was reversed
to ensure comparable groups. A more optimal conven-
tional randomisation methodology, that is randomly allo-
cating individual study participants to one of the two
treatment groups at recruitment, was not possible for this
study. It was decided by the study development team that
it would not be feasible or practical to attempt to do this
in the selected setting. Lack of specific local support for
randomisation and concerns about the impact on the
credibility and fidelity of the study interventions were
identified as problematic issues if individual participant
randomisation were adopted. The selected quasi random-
isation approach, where treatment allocation was based on
the month surgery was undertaken, although not as rigor-
ous, was selected as the only practical option for this
study. Due to the unpredictable nature of the injury and
short time interval between injury and surgery, there was
no reason to believe that the selected method of treatment
allocation would impact on treatment effect estimates.
Within this study setting it was impossible to blind the op-
erating surgeon, as an experienced surgeon may be able to
tell the difference between the cement, even though the
characteristics are very similar, the handling characteristics
could potentially be different and the surgeon would need
to be aware. Additionally the boxes were not blinded and
therefore the surgeon could see the type of cement used.
The study participants, research nurses involved in re-
cruitment and assessment, and clinical staffs involved in
the care of study participants were all blind to treatment
allocation throughout the study.
Interventions
Hip hemiarthroplasty participants
Before the operation, all patients followed the same
pathway from Accident and Emergency to the ward and
the same preoperative optimisation process prior to the
operation. To ensure that the trial results could be gen-
eralised to as wide a group of patients as possible, eachpatient had the allocated surgery according to the pre-
ferred technique of the operating surgeon. Prophylactic
parenteral antibiotics prophylaxis at the start of trial was
Gentamicin (4.5 mg/kg) and this was changed to Genta-
micin (3 mg/kg) and Teicoplanin (400 mg) in February
2009 [13] in line with our trust prophylaxis for primary
joint replacement. Antibiotics were given as a single
dose, within 30 minutes of induction.
Standard care group
This study is pragmatic in design and we did not stipu-
late methods of analgesia and anaesthesia, or post-
operative care. A standard hemiarthroplasty implant was
used in every case. Methylmethacrylate cement with low
dose antibiotics (0.5 g of Gentamicin) with normal
viscosity was inserted using a simple retrograde tech-
nique, with a cement restrictor. In order to maintain
consistency of antibiotic release a commercial product
was used, rather than the antibiotic being added by the
surgeon [14].
Intervention group
The intervention group received exactly the same regi-
men as the standard of care group, except they receive
Methylmethacrylate cement impregnated with high dose
antibiotics. This cement consists of 1 g Clindamycin and
1 g of Gentamicin. The cement is a commercial product,
from the same company to maintain consistency of anti-
biotic release [15].
Risks
No additional risks for study patients were expected,
since all surgical procedures carried out within FHIT
represent clinically established standard methods of
treatment of fractured neck of femur.
Primary outcome measure
The primary outcome is SSI infection based upon Health
Protection Agency (HPA) published definitions, which
originate from the Centers for Disease Control and
Prevention (CDC) 1992 published definition. The HPA
criteria are the nationally agreed definition used within
the UK, and routinely collected by the majority of UK
Trusts. Deep incisional infection is defined as a surgical
site infection involving the deep tissues (i.e. fascial and
muscle layers) that occurs within 30 days of surgery if
no implant is in place, or within a year if an implant is
in place, the infection appears to be related to the surgi-
cal procedure, and meets at least one of the criteria in
Table 1.
Secondary outcome measures
Superficial incisional infection is defined by the HPA, as
a surgical site infection that occurs within 30 days of
Table 1 Health protection agency definition of superficial and deep surgical site infection
Superficial incisional infection Deep incisional infection
SSI that occurs within 30 days of surgery, involves only the skin or
subcutaneous tissue of the incision & meets at least one of the
following criteria:
SSI involving the deep tissues (i.e. fascial & muscle layers), within 30 days
of surgery (or 1 year if an implant is in place) and the infection appears
to be related to the surgical procedure & meets at least one of the
following criteria:
1. Purulent drainage from superficial incision 1. Purulent drainage from deep incision (not organ space)
2. Culture of organisms and pus cells present: 2. Organisms from culture and pus cells present in:
fluid / tissue from superficial incision wound swab from superficial
incision
Fluid / tissue from deep incision or wound swab from deep incision
3. At least 2 symptoms of inflammation: 3. Deep incision dehisces or deliberately opened and patient has at least
1 symptom of:
Pain, tenderness, localised swelling, redness, heat and either:
1) Incision deliberately opened to manage infection Fever or localised pain/tenderness
OR 4. Abscess or other evidence of infection in deep incision:
Re-operation / histopathology / radiology
2) Clinicians diagnosis of superficial SSI 5. Clinicians diagnosis of deep incisional SSI
Note: Stitch abscesses (minimal inflammation/discharge at suture point)
do not classify as SSI
Note: An infection involving both superficial and deep incisional = deep
incisional inflammation/discharge at suture point) do not classify as SSI
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sue of the incision, and meets at least one of the criteria
in Table 1.
Length of hospital stay
This is calculated from participant’s admission and dis-
charge dates.
30 and 90-day mortality
Mortality data were obtained from the Office of National
Statistics (ONS). In England, deaths must be registered
within 5 days. Burials and cremations cannot be con-
ducted without this registration documentation. These
deaths are recorded by the ONS and are added to the
patient’s health service record.
Medical and surgical complications
This data is recorded from hospital records during the
in-patient stay, and utilising Hospital Episode Statistics
data for readmission, further surgical admission, re oper-
ation up to 12-months post-operative. If participants re-
port the occurrence of a complication at any point
within the 12- month’s post-operative, this is verified by
a review of their hospital records.
Pre operative patient factors
A number of possible potential prognostic factors are
being recorded, including socio-demographic factors and
medical co-morbidities.
Specific post operative complications
An additional number of specific complications are be-
ing recorded such as Deep Vein Thrombosis (DVT) at
60 days, Pulmonary Embolism (PE) at 60 days, stroke at30 days, Transient Ischemic Attack (TIA) at 30 days, GI
Bleed at 30 days (GIB), Urinary Retention at 30 days
(UR), Urinary tract infection (UTI) at 30 days, Myocar-
dial Infarction (MI) at 30 days, Pneumonia at 30 days
(RTI), and readmission rate.
Acute Renal Failure at 30 days (ARF) and C. Difficile
rates will also be recorded, due to potential adverse
events related to higher doses of antibiotics impregnated
within the intervention cement.Delay to surgery
Delay to surgery was measured in both groups to ensure
this was unaffected by treatment allocation.Sample size calculation
The primary outcome for this trial is deep SSI based on
the HPA defined criteria at 12-months post-operation.
Eight hundred and forty eight patients listed for hip
hemiarthroplasty are being recruited into the study, and
quasi randomised to the intervention arm or the stand-
ard care arm. At the initiation of the study the national
rate of SSI was 4.68% for hip hemiarthroplasty, based
upon Health Protection Agency data. The research team
also analyzed the organisms causing infection within this
setting, and the border spectrum of antibiotics covered
90% of these organisms. This sample size will provide
80% power to detect a reduction of SSI infection from
4% to 1%, at the 5% level. This significant effect size has
been documented within our intervention cement in
infected single stage revisions where it is able to eradi-
cate infections in about 80% of cases. This difference
represents a significant reduction, which would have an
important clinical impact.
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A CONSORT diagram [16] will summarise participant
flow through the study, documenting eligibility and re-
cruitment, receipt of intervention or standard care as al-
located, and collection of data [17]. Standard statistical
summaries (e.g. medians and ranges or means and vari-
ances, dependent on the distribution of the outcome)
and graphical plots showing correlations will be pre-
sented for the primary outcome measure and all second-
ary outcome measures. Baseline data will be summarised
to check comparability between treatment arms, and to
highlight any characteristic differences between those indi-
viduals in the study, those ineligible, and those eligible but
withholding consent. Although missing data is not ex-
pected to be a major issue for this study, the nature and
pattern of the missingness will be carefully considered —
including in particular whether data can be treated as
missing completely at random (MCAR). If judged appro-
priate, missing data will be imputed, and resulting im-
puted datasets will be analysed and reported, together
with appropriate sensitivity analyses. Formal analysis, for
example using logistic regression with ‘missingness’ as a
response, may also be appropriate and aid interpretation.
The primary outcome, deep infections, will be com-
pared between treatment groups using logistic regression
analysis, adjusting for both participant age and gender;
regression coefficients will be considered to be signifi-
cant if p-values are less than 0.05 (5% significance level).
Estimates of treatment effects will be presented with
95% confidence intervals. Although generally we have no
reason to expect that the clustering effects will be import-
ant for this study, in reality the data will be hierarchical in
nature, with patients naturally clustered into groups by
operating surgeon. Therefore we propose to account for
this by generalizing the conventional linear (fixed-effects)
logistic regression approach to a more general mixed-
effects modelling approach where patients are naturally
grouped by surgeons; i.e. a random effect is included in
the model to account for heterogeneity due to the operat-
ing surgeon. This analysis will be presented in addition to
the conventional fixed effects model. All analyses will be
conducted on an intention-to-treat (ITT) basis, and
reported as such; additional per-protocol analyses will be
undertaken and reported if these prove to be informative.
Any subsequent amendments to this initial SAP will
be clearly stated and justified. Interim analyses will be
performed only where directed by the data monitoring
committee (DMC). The routine statistical analysis will
mainly be carried out using R (http://www.r-project.org/)
and S-PLUS (http://www.insightful.com/).
Discussion
Surgical site infection in this vulnerable group of pa-
tients is associated with increased mortality, morbidity,and pain, which are well documented, in the inter-
national literature [18]. For patients undergoing this pro-
cedure, reduction of postoperative complications should
be a targeted objective for orthopaedic surgeons [19].
There is great heterogeneity relating to patient pathways
once a fractured NOF has occurred, making a suitable
intervention difficult to isolate. A targeted intervention
ideally needs to be easily adopted, low-intensity, independ-
ent of local hospital policy, and surgeon factors [20]. One
of the great potencies of this trial is the ease with which
the intervention could be applied pragmatically into any
hospital in the NHS.
The number of patients who develop deep and super-
ficial SSI will continue to increase as the number of fra-
gility fractures increases, and therefore it is important
that interventions optimise outcomes after surgery are
evaluated. Pragmatic RCTs represent the highest level
of evidence to assess the effectiveness of an orthopaedic
intervention. However, there is a scarcity of well-
designed and sufficiently powered RCTs of orthopaedic
interventions, in particular with orthopaedic infections.
Many orthopaedic trials fail to be delivered due to lack
of scientific rigor in study design and execution. FHIT
is a pragmatic trial which cannot blind the surgeon,
however an appropriate sample size has been calculated,
outcome assessors are blinded, clear inclusion and ex-
clusion criteria defined, and information on statistical
analysis considered appropriately. The FHIT trial has
been designed to demonstrate a clinically important
difference for patients, surgeons and within the wider
setting of the NHS.
The primary aim of the FHIT trial is to determine if
the addition of high dose antibiotic impregnated ce-
ment to the standard regime at Northumbria NHS trust
can significantly reduce SSI at 12-months after hip
hemiarthroplasty. The results from this trial will inform
evidence-based recommendations for patients with an
intracapsular fractured neck of femur treated with a
hemiarthroplasty. If high dose antibiotic impregnated
cement is found to be an effective intervention, its im-
plementation into clinical practice could reduce SSI
after hemiarthroplasty, and therefore improve long-
term outcomes for patients suffering from this fragility
fracture.Abbreviations
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